We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
+21.1%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.86B
AUM Growth
-$150M
(-5%)
Cap. Flow
-$428M
Cap. Flow
% of AUM
-14.96%
Top 10 Holdings %
Top 10 Hldgs %
28.09%
Holding
113
New
30
Increased
18
Reduced
43
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE HealthCare
GEHC
|
+$83.4M |
| 2 |
AbbVie
ABBV
|
+$76M |
| 3 |
Eli Lilly
LLY
|
+$55.8M |
| 4 |
Pfizer
PFE
|
+$43.5M |
| 5 |
APLS
Apellis Pharmaceuticals
APLS
|
+$40.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$72.7M |
| 2 |
Surgery Partners
SGRY
|
+$68.7M |
| 3 |
AKRO
Akero Therapeutics
AKRO
|
+$65.2M |
| 4 |
Merck
MRK
|
+$63.8M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
+$56.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.98% |
| 2 | Technology | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
MoonLake Immunotherapeutics
MLTX
$1.66B
| $20.4M | 0.71% |
+400,000
| New | +$10.8M |
|
|
VRNA
52
DELISTED
Verona Pharma
VRNA
| $20.2M | 0.7% |
954,500
+75,700
| +9% | +$1.61M |
|
53
Amylyx Pharmaceuticals
AMLX
$2.06B
| $19.4M | 0.68% |
901,400
+1,400
| +0.2% | +$37.8K |
|
|
AXNX
54
DELISTED
Axonics, Inc. Common Stock
AXNX
| $19.2M | 0.67% |
+379,700
| New | +$20.2M |
|
55
Xenon Pharmaceuticals
XENE
$6.35B
| $18.5M | 0.65% |
+481,300
| New | +$19.1M |
|
|
56
Regeneron Pharmaceuticals
REGN
$70.6B
| $17.8M | 0.62% |
24,800
-94,300
| -79% | -$72.7M |
|
57
Roivant Sciences
ROIV
$25B
| $17M | 0.59% |
+1,687,500
| New | +$15.1M |
|
58
Pliant Therapeutics
PLRX
$66.9M
| $16.6M | 0.58% |
916,600
-1,748,400
| -66% | -$41.4M |
|
|
VERV
59
DELISTED
Verve Therapeutics
VERV
| $16.5M | 0.58% |
878,600
-473,100
| -35% | -$7.88M |
|
60
Intellia Therapeutics
NTLA
$1.51B
| $16.1M | 0.56% |
395,855
-21,145
| -5% | -$857K |
|
|
CERE
61
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $15.9M | 0.56% |
+501,200
| New | +$15.4M |
|
|
SLRN
62
DELISTED
ACELYRIN
SLRN
| $15.7M | 0.55% |
+750,000
| New | +$15.3M |
|
|
PNT
63
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $15.1M | 0.53% |
1,671,800
-739,800
| -31% | -$6.52M |
|
64
Karyopharm Therapeutics
KPTI
$165M
| $15M | 0.52% |
558,007
-84,254
| -13% | -$3.63M |
|
|
KZR
65
DELISTED
Kezar Life Sciences
KZR
| $14.9M | 0.52% |
608,000
-43,940
| -7% | -$1.14M |
|
66
Schrodinger
SDGR
$1.14B
| $13.7M | 0.48% |
+274,900
| New | +$9.29M |
|
|
TSVT
67
DELISTED
2seventy bio
TSVT
| $13.6M | 0.47% |
+1,342,000
| New | +$14.2M |
|
68
Mineralys Therapeutics
MLYS
$2.46B
| $13.1M | 0.46% |
766,700
-497,100
| -39% | -$7.43M |
|
|
MRSN
69
DELISTED
Mersana Therapeutics
MRSN
| $12.5M | 0.44% |
151,600
+14,271
| +10% | +$2.09M |
|
70
Caribou Biosciences
CRBU
$162M
| $11.7M | 0.41% |
2,758,600
| – | – |
|
|
NSTG
71
DELISTED
NanoString Technologies, Inc.
NSTG
| $10.9M | 0.38% |
2,700,400
+483,400
| +22% | +$3.57M |
|
|
ALPN
72
DELISTED
Alpine Immune Sciences Inc
ALPN
| $10.9M | 0.38% |
1,058,500
+69,000
| +7% | +$622K |
|
|
NARI
73
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $10.2M | 0.36% |
+175,000
| New | +$11M |
|
|
ETNB
74
DELISTED
89bio
ETNB
| $9.97M | 0.35% |
526,376
-1,316,600
| -71% | -$23.1M |
|
75
AC Immune
ACIU
$236M
| $8.58M | 0.3% |
2,903,278
+2,577,878
| +792% | +$5.63M |
|
Similar funds
NM
PWAM
LJAC
NI
MCM
TS
TW
PGA
Avidity Partners Management's Q2 2023 Portfolio in Review
As of Q2 2023, Avidity Partners Management held 113 positions worth $2.86B, down 5% from $3.01B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Avidity Partners Management withdrew a net $428M in Q2 2023, closing 20 positions and reducing 43 holdings. Its most notable exit was Merck, an estimated $63.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology.
Against the trend, Avidity Partners Management opened a new position in GE HealthCare worth $84.9M.
- Avidity Partners Management's largest Q2 2023 buy was GE HealthCare: 1,045,400 shares worth $84.9M.
- Avidity Partners Management added most to Cencora in Q2 2023, an estimated $30M increase.
- Avidity Partners Management's biggest Q2 2023 reduction was Regeneron Pharmaceuticals, cutting an estimated $72.7M.
- Avidity Partners Management fully exited Merck in Q2 2023, selling an estimated $63.8M.
- Avidity Partners Management's ten largest holdings make up 28% of its $2.86B portfolio in Q2 2023.
- Avidity Partners Management opened 30 new positions and closed 20 in Q2 2023.
- Avidity Partners Management's portfolio value fell 5% quarter-over-quarter to $2.86B.
Based on Avidity Partners Management's 13F filing for Q2 2023, filed 14 Aug 2023.